Methods for treating cancer by activation of BMP signaling

• US 9,814,703 B2
• Filed: 11/13/2014
• Issued: 11/14/2017
• Est. Priority Date: 11/14/2013
• Status: Active Grant

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Inventors: Beachy, Philip A., Shin, Kunyoo
• Primary Examiner(s): Murray, Jeffrey H
• Application Number:
  US15/147,719
• Publication Number:
  US 20170119740A1
• Time in Patent Office: 1,097 Days
• Field of Search: 514183
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/33 Heterocyclic compounds
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L

Abstract

Methods for treating cancer by activation of the Bmp pathway are disclosed. In particular, the invention relates to methods of treating cancer using agents that activate BMP signaling, e.g., FK506 (tacrolimus), to treat a subject for cancer.

Claims

1. A method of treating a subject for bladder cancer, the method comprising administering a therapeutically effective amount of FK506 to the subject.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1, wherein the effective amount of an agent that activates BMP signaling is administered prophylactically to the subject.

4. The method of claim 3, wherein the prophylactic administration delays progression of a bladder cancer to an invasive cancer.

5. The method of claim 4, wherein the bladder cancer is a carcinoma and the invasive cancer is an invasive carcinoma.

6. The method of claim 1, wherein multiple cycles of the method of treatment are administered to said subject for a time period sufficient to effect at least a partial tumor response.

7. The method of claim 6, wherein the time period is at least 6 months.

8. The method of claim 7, wherein the time period is at least 12 months.

9. The method of claim 6, wherein a complete tumor response is effected.

10. The method of claim 1, wherein the FK506 is administered subcutaneously.

11. The method of claim 1, wherein low dose therapy is administered to the subject to avoid immunosuppression.

12. The method of claim 1, wherein the method further comprises administering a modulator of Hh signaling to the subject.

13. The method of claim 12, wherein the modulator of Hh signaling is a Hh antagonist.

14. The method of claim 12, wherein the modulator of Hh signaling is a Hh agonist.